Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00567749 |
Recruitment Status
:
Completed
First Posted
: December 5, 2007
Last Update Posted
: June 27, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV Infections |
In order to achieve the primary objective, clinical trials will be conducted to establish and confirm the sensitivity of the Clearview HIV 1/2 tests in the described pediatric population. Only HIV-1 will be included in the study.
The Clearview HIV tests can be used as a safe and effective screening method to aid in the diagnosis of infection with HIV 1/2 in the pediatric population aged between 12 and 17 years.
The secondary objectives of this study include demonstrating that:
- The Clearview HIV tests detect HIV-1 antibodies in a variety of sample matrices: capillary (fingertip) whole blood, venous whole blood, plasma and serum.
Study Type : | Observational |
Actual Enrollment : | 10 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Clinical Sensitivity of the Clearview® COMPLETE HIV 1/2, PMA # BP050009 and the Clearview® HIV 1/2 STAT-PAK®, PMA #BP050010 in the 12 - 17 Year Old Pediatric Population |
Study Start Date : | December 2007 |
Actual Primary Completion Date : | June 2008 |
Actual Study Completion Date : | June 2008 |

Group/Cohort |
---|
A, Observational |
- The Clearview HIV tests provide a 100% agreement with known HIV(+) status for all 10 eligible 12 to 17 year old individuals, at least one of whom will be age 12. [ Time Frame: 3-10 days ]
- The Clearview tests will be used in a representative clinical setting for the qualitative detection of antibodies to HIV-1 in fingerstick, venous whole blood, serum and plasma matrices. [ Time Frame: 3-10 days ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Must be at least 12 years of age and no older than 17 years of age.
- Must be willing to sign (and be given) a copy of the written Information and Assent Form.
- Must have a parent or guardian present to sign and receive a copy of the Informed Consent Form.
- Must be able to provide one or two fingerstick blood samples.
- Must be able to provide three tubes of blood by venipuncture from the arm or hand only.
Exclusion Criteria:
- Have a life threatening illness (with the exception of HIV or AIDS).
- Have a suppressed immune systems (i.e. transplant patients, individuals diagnosed with non-HIV immunosuppressive illness, etc.), as determined by interviewing the study participant or parent/legal guardian.
- Have participated or are participating in a clinical trial for an HIV vaccine (as determined by interviewing the study participant or parent/legal guardian).
- Have previously participated in this clinical trial (no duplicate enrollments).
- Are currently on HAART, except as agreed on a case-by-case basis.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00567749
United States, Maryland | |
Laboratory of Viral Diagnostics, University of Maryland School of Medicine | |
Baltimore, Maryland, United States, 21201 |
Principal Investigator: | Neil T. Constantine, Ph.D. | University of Maryland |
Responsible Party: | Thomas D. Ippolito / VP Regulatory Affairs, Chembio Diagnostic Systems, Inc. |
ClinicalTrials.gov Identifier: | NCT00567749 History of Changes |
Other Study ID Numbers: |
02-HIV02.01 |
First Posted: | December 5, 2007 Key Record Dates |
Last Update Posted: | June 27, 2008 |
Last Verified: | June 2008 |
Keywords provided by Chembio Diagnostic Systems, Inc.:
HIV-1 Infections |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |